Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 46 条
  • [1] Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022
    Vikse, Elisabeth Lea
    Fossum, Even
    Erdal, Magnhild Sekse
    Hungnes, Olav
    Bragstad, Karoline
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (06)
  • [2] Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
    Bellusci, Lorenza
    Grubbs, Gabrielle
    Sait, Shaimaa
    Yonker, Lael M.
    Randolph, Adrienne G.
    Novak, Tanya
    Kobayashi, Takuma
    Khurana, Surender
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
    Tauzin, Alexandra
    Benlarbi, Mehdi
    Medjahed, Halima
    Gregoire, Yves
    Perreault, Josee
    Gendron-Lepage, Gabrielle
    Gokool, Laurie
    Morrisseau, Chantal
    Arlotto, Pascale
    Tremblay, Cecile
    Kaufmann, Daniel E.
    Martel-Laferriere, Valerie
    Levade, Ines
    Cote, Marceline
    De Serres, Gaston
    Bazin, Renee
    Finzi, Andres
    VACCINES, 2023, 11 (02)
  • [4] Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
    Varghese, Ryan
    Kumar, Dileep
    Sharma, Rohit
    HUMAN CELL, 2023, 36 (03) : 1218 - 1221
  • [5] Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
    Ryan Varghese
    Dileep Kumar
    Rohit Sharma
    Human Cell, 2023, 36 : 1218 - 1221
  • [6] Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
    Entzminger, Kevin C.
    Fleming, Jonathan K.
    Entzminger, Paul D.
    Espinosa, Lisa Yuko
    Samadi, Alex
    Hiramoto, Yuko
    Okumura, Shigeru C. J.
    Maruyama, Toshiaki
    ANTIBODY THERAPEUTICS, 2023, 6 (02) : 108 - 118
  • [7] Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections
    Kurahashi, Yukiya
    Sutandhio, Silvia
    Furukawa, Koichi
    Tjan, Lidya Handayani
    Iwata, Sachiyo
    Sano, Shigeru
    Tohma, Yoshiki
    Ohkita, Hiroyuki
    Nakamura, Sachiko
    Nishimura, Mitsuhiro
    Arii, Jun
    Kiriu, Tatsunori
    Yamamoto, Masatsugu
    Nagano, Tatsuya
    Nishimura, Yoshihiro
    Mori, Yasuko
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
    Sullivan, David J.
    Franchini, Massimo
    Senefeld, Jonathon W.
    Joyner, Michael J.
    Casadevall, Arturo
    Focosi, Daniele
    JOURNAL OF GENERAL VIROLOGY, 2023, 104 (05)
  • [9] Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
    Hernandez-Luis, Pablo
    Aguilar, Ruth
    Pelegrin-Perez, Judit
    Ruiz-Olalla, Gemma
    Garcia-Basteiro, Alberto L.
    Tortajada, Marta
    Moncunill, Gemma
    Dobano, Carlota
    Angulo, Ana
    Engel, Pablo
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
    Kurahashi, Yukiya
    Furukawa, Koichi
    Sutandhio, Silvia
    Tjan, Lidya Handayani
    Iwata, Sachiyo
    Sano, Shigeru
    Tohma, Yoshiki
    Ohkita, Hiroyuki
    Nakamura, Sachiko
    Nishimura, Mitsuhiro
    Arii, Jun
    Kiriu, Tatsunori
    Yamamoto, Masatsugu
    Nagano, Tatsuya
    Nishimura, Yoshihiro
    Mori, Yasuko
    JOURNAL OF INFECTIOUS DISEASES, 2022, : 1391 - 1395